Subtype Report on Hodgkin Lymphoma

HL is primarily a curable cancer and with current treatments, 80% to 90% of patients can achieve permanent remission. The mainstay of treatment is multi-agent chemotherapy often in combination with radiation therapy. With high treatment responses, focus is now being made to improve long term morbidity issues.

In the past decade there has been a greater understanding of the tumour microenvironment and the overall biology of HL. The discovery of the B-cell identity of HRS and its signaling pathways have the potential to be exploited therapeutically.

It is imperative that novel therapies are made available to all patients no matter where they live. There are huge discrepancies in access and outcome between countries and regions.

 

subtype report hodgkin lymphoma

Click here to view the report.

 


For additional information and support for patients with HL, download and install the LyfeApp on GooglePlay and in the App Store for iOS.


 

Global Database Search

 knowyoursubtype iconb   facebook2 twitter2 youtube1

logo europe

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 05/30/17. Copyright © 2017 Lymphoma Coalition. All rights reserved.